# US 2021/0171637 A1 · Anti-b7-h3 antibodies and antibody drug conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171637 A1
- Document ID: US20210171637A1
- Status: Published application
- Kind: A1
- Application number: 16/819,036
- Filed: 2020-03-13
- Published: 2021-06-10
- Earliest claimed: 2016-06-08
- Assignees: AbbVie Inc.
- Applicants: AbbVie Inc.
- Inventors: Lorenzo Benatuil; Debra Chao; Kamel Izeradjene; Andrew S. Judd; Andrew C. Phillips; Andrew J. Souers; Archana Thakur; Milan Bruncko
- Web page: https://patentgrep.com/patent/US20210171637A1

## CPC

- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/68031: {the drug being an auristatin}
- A61K 47/68035: {the drug being a pyrrolobenzodiazepine}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6877: {the antibody being an immunoglobulin containing regions, domains or residues from different species}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/51: Complete heavy chain or Fd fragment, i.e. VH + CH1
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/55: containing a fusion with a toxin, e.g. diphteria toxin
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.

## Claims

### Claim 1

An isolated anti-hB7H3 antibody, wherein the antibody comprises
a heavy chain variable region comprising
a CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 35, and SEQ ID NO: 27.
and a light chain variable region comprising
a CDR3 having an amino acid sequence selected from the group consisting of of SEQ ID NO: 15, SEQ ID NO: 39, and SEQ ID NO: 31;
a CDR2 having an amino acid sequence selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 38, and SEQ ID NO: 30; and
a CDR1 having an amino acid sequence selected from the group consisting of SEQ ID NO: 136, SEQ ID NO: 138, SEQ ID NO: 37, SEQ ID NO: 14, and SEQ ID NO: 29.

### Claim at position 2

2-12. (canceled)

### Claim 13 (depends on 1)

The antibody according to claim 1, wherein the antibody further comprises a human acceptor framework and said human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID 155, 156, 164, 165, 166, and 167.

### Claim at position 4

14-22. (canceled)

### Claim 23 (depends on 1)

The antibody according to claim 1, wherein the antibody further comprises a human acceptor framework and said human acceptor framework comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 155 to 158.

### Claim at position 6

24-31. (canceled)

### Claim 32 (depends on 1)

The anti-hB7-H3 antibody according to claim 1, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 135.

### Claim 33

(canceled)

### Claim 34 (depends on 1)

The anti-hB7-H3 antibody according to claim 1, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 139 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 137.

### Claim 35

(canceled)

### Claim 36 (depends on 1)

The anti-hB7-H3 antibody according to claim 1, wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 147 and a light chain variable domain comprising an amino acid sequence set forth in SEQ ID NO: 144.

### Claim at position 12

37-129. (canceled)

### Claim 130 (depends on 1)

The isolated antibody according to claim 1, wherein the antibody, or antigen binding portion thereof, comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 168 and a light chain comprising the amino acid sequence of SEQ ID NO: 169.

### Claim 131 (depends on 1)

The isolated antibody, according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 170 and a light chain comprising the amino acid sequence of SEQ ID NO: 171.

### Claim 132 (depends on 1)

The isolated antibody according to claim 1, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 172 and a light chain comprising the amino acid sequence of SEQ ID NO: 173.

### Claim at position 16

133-137. (canceled)
